{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:16:42Z","timestamp":1792019802899,"version":"4.4.0"},"reference-count":128,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Metabolic dysfunction-associated fatty liver disease (MASLD) is a rising global health concern. In addition to direct hepatic complications, extra-hepatic complications, including cardiovascular diseases (CVD), type 2 diabetes (T2D), gastroesophageal reflux disease, chronic kidney disease and some malignancies, are increasingly recognized. CVD, including atrial fibrillation (AF) and heart failure (HF), is the leading cause of death in patients with MASLD. External factors, including excess energy intake, sedentary lifestyle and xenobiotic use, induce inflammation-related complications. MASLD, AF, and HF are associated with immune system activation, including the reprogramming of immune cells and the establishment of immune memory. Emerging evidence suggests that the heart and the liver cross-talk with each other through the diverse spectrum of autocrine, paracrine and endocrine mechanisms. Pro-inflammatory cytokines produced from the liver and the heart circulate systemically to orchestrate metabolic derangements that promote the systematic immune dysregulation in the heart-liver axis and the development of end-organ complications. Cardio-hepatic syndrome describes the clinical and biochemical evidence of hepatic dysfunction and cardiac pathology due to the interaction between the heart and the liver. Activation of inflammatory cascades, oxidative stress and immune system dysregulation underlie key mechanisms in bringing about such pathological changes. This review focuses on the current clinical and molecular evidence about the heart-liver cross-talk. It summarizes the epidemiological and pathophysiological associations of MASLD, AF and HF. In addition, we will discuss how repurposing currently available and emerging pharmacotherapies may help tackle the cardiovascular risks resulting from MASLD.<\/jats:p>","DOI":"10.3389\/fcvm.2025.1573841","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T01:18:17Z","timestamp":1744075097000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Role of metabolic dysfunction-associated fatty liver disease in atrial fibrillation and heart failure: molecular and clinical aspects"],"prefix":"10.3389","volume":"12","author":[{"given":"Jamie","family":"Cheung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard Man-Yung","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Hang","family":"Yiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Fat","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yap-Hang","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1093\/ehjqcco\/qcaa061","article-title":"Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990\u20132017: results from the global burden of disease study 2017","volume":"7","author":"Dai","year":"2020","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"B4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1161\/CIRCRESAHA.121.318172","article-title":"Epidemiology of heart failure: a contemporary perspective","volume":"128","author":"Roger","year":"2021","journal-title":"Circ Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals","volume":"391","author":"Conrad","year":"2018","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.26599\/1671-5411.2024.06.008","article-title":"Heart failure in China: epidemiology and current management","volume":"21","author":"Hu","year":"2024","journal-title":"J Geriatr Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"706978","DOI":"10.3389\/fendo.2021.706978","article-title":"Obesity: epidemiology, pathophysiology, and therapeutics","volume":"12","author":"Lin","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/ehjci\/jeab059","article-title":"Prognostic value and reversibility of liver stiffness in patients undergoing tricuspid annuloplasty","volume":"23","author":"Chen","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B10","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jcmg.2017.10.022","article-title":"Liver stiffness reflecting right-sided filling pressure can predict adverse outcomes in patients with heart failure","volume":"12","author":"Taniguchi","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"B11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cardfail.2019.01.020","article-title":"Relationship of liver stiffness with congestion in patients presenting with acute decompensated heart failure","volume":"25","author":"Soloveva","year":"2019","journal-title":"J Card Fail"},{"key":"B12","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.amjcard.2015.11.030","article-title":"Relation of tricuspid regurgitation to liver stiffness measured by transient elastography in patients with left-sided cardiac valve disease","volume":"117","author":"Chen","year":"2016","journal-title":"Am J Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1093\/eurheartj\/ehae346","article-title":"Secondary tricuspid regurgitation: incidence, types, and outcomes in atrial fibrillation vs. sinus rhythm","volume":"45","author":"Naser","year":"2024","journal-title":"Eur Heart J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1002\/ehf2.15019","article-title":"Non-alcoholic fatty liver disease and heart failure: a comprehensive bioinformatics and Mendelian randomization analysis","volume":"11","author":"Zhang","year":"2024","journal-title":"ESC Heart Fail"},{"key":"B15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejim.2022.07.007","article-title":"Causal effect of non-alcoholic fatty liver disease on atrial fibrillation","volume":"105","author":"Chen","year":"2022","journal-title":"Eur J Intern Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41418-022-01062-4","article-title":"Cell death and inflammation during obesity: \u201cknow my methods, WAT(son)\u201d","volume":"30","author":"Hildebrandt","year":"2023","journal-title":"Cell Death Differ"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e837","DOI":"10.1161\/CIRCULATIONAHA.111.077602","article-title":"Ectopic fat depots and cardiovascular disease","volume":"124","author":"Britton","year":"2011","journal-title":"Circulation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41577-024-01103-8","article-title":"Adipokines: masterminds of metabolic inflammation","volume":"25","author":"Tilg","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41569-022-00679-9","article-title":"Epicardial adipose tissue in contemporary cardiology","volume":"19","author":"Iacobellis","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s12276-020-0438-5","article-title":"Recent advances of sterile inflammation and inter-organ cross-talk in alcoholic liver disease","volume":"52","author":"Shim","year":"2020","journal-title":"Exp Mol Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3390\/nu15051123","article-title":"The inter-organ crosstalk reveals an inevitable link between MAFLD and extrahepatic diseases","volume":"15","author":"Tsutsumi","year":"2023","journal-title":"Nutrients"},{"key":"B22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41574-022-00641-2","article-title":"Exerkines in health, resilience and disease","volume":"18","author":"Chow","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jchf.2018.10.007","article-title":"Heart failure and liver disease","volume":"7","author":"Xanthopoulos","year":"2019","journal-title":"JACC Heart Fail"},{"key":"B24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ccc.2016.02.004","article-title":"The circulatory system in liver disease","volume":"32","author":"Hollenberg","year":"2016","journal-title":"Crit Care Clin"},{"key":"B25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/hrt.13.3.273","article-title":"The liver in heart failure; relation of anatomical, functional, and circulatory changes","volume":"13","author":"Sherlock","year":"1951","journal-title":"Br Heart J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41574-019-0256-9","article-title":"The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state","volume":"15","author":"Hodson","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0008-6363(99)00263-1","article-title":"Cardiac fatty acid uptake and transport in health and disease","volume":"45","author":"van der Vusse","year":"2000","journal-title":"Cardiovasc Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1093\/cvr\/cvad100","article-title":"Cardiac lipid metabolism, mitochondrial function, and heart failure","volume":"119","author":"Da Dalt","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"100130","DOI":"10.1016\/j.ajpc.2020.100130","article-title":"Inflammation and cardiovascular disease: from mechanisms to therapeutics","volume":"4","author":"Alfaddagh","year":"2020","journal-title":"Am J Prev Cardiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"286","DOI":"10.31083\/j.fbl2908286","article-title":"Mechanism of action and risk prediction of adiponectin in cardiovascular diseases","volume":"29","author":"Li","year":"2024","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Hagstr\u00f6m","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s12072-023-10590-1","article-title":"How non-alcoholic fatty liver disease and cirrhosis affect the heart","volume":"17","author":"M\u00f8ller","year":"2023","journal-title":"Hepatol Int"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1111\/liv.13394","article-title":"Bile acids and cardiovascular function in cirrhosis","volume":"37","author":"Voiosu","year":"2017","journal-title":"Liver Int"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.bbadis.2017.12.039","article-title":"Heart and bile acids\u2014clinical consequences of altered bile acid metabolism","volume":"1864","author":"Vasavan","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3892\/mmr.2024.13219","article-title":"Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation-mediating treatment options (review)","volume":"29","author":"Varra","year":"2024","journal-title":"Mol Med Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1002\/ejhf.1294","article-title":"The epicardial adipose inflammatory triad: coronary atherosclerosis, atrial fibrillation, and heart failure with a preserved ejection fraction","volume":"20","author":"Packer","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"B37","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/ehf2.14982","article-title":"Biomarkers of lung congestion and injury in acute heart failure","volume":"12","author":"Guazzi","year":"2024","journal-title":"ESC Heart Fail"},{"key":"B38","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/MAJ.0b013e318232750d","article-title":"Congestive heart failure: pathophysiologic consequences of neurohormonal activation and the potential for recovery: part I","volume":"342","author":"Dube","year":"2011","journal-title":"Am J Med Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.cjca.2019.04.007","article-title":"Role of IL-37 in cardiovascular disease inflammation","volume":"35","author":"Yang","year":"2019","journal-title":"Can J Cardiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1006\/phrs.1998.0463","article-title":"The role of TNF in cardiovascular disease","volume":"40","author":"Ferrari","year":"1999","journal-title":"Pharmacol Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.3390\/nu16172822","article-title":"The role of inflammatory mediators in the pathogenesis of obesity","volume":"16","author":"Bakinowska","year":"2024","journal-title":"Nutrients"},{"key":"B42","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.cytogfr.2018.08.003","article-title":"Cytokines as therapeutic agents and targets in heart disease","volume":"43","author":"Dubnika","year":"2018","journal-title":"Cytokine Growth Factor Rev"},{"key":"B43","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/00132580-200109000-00008","article-title":"The role of tumor necrosis factor in cardiac disease","volume":"3","author":"Retter","year":"2001","journal-title":"Heart Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1093\/eurheartj\/ehy128","article-title":"Interleukin-1 blockade in cardiovascular diseases: a clinical update","volume":"39","author":"Buckley","year":"2018","journal-title":"Eur Heart J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jhep.2024.06.016","article-title":"Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation","volume":"81","author":"Taru","year":"2024","journal-title":"J Hepatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.imlet.2016.05.001","article-title":"IL-17+ CD8+ T cells: differentiation, phenotype and role in inflammatory disease","volume":"178","author":"Srenathan","year":"2016","journal-title":"Immunol Lett"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1470362","DOI":"10.3389\/fcvm.2024.1470362","article-title":"The role of IL-17 family cytokines in cardiac fibrosis","volume":"11","author":"Huang","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3390\/biom9080345","article-title":"IL-38: a new player in inflammatory autoimmune disorders","volume":"9","author":"Xie","year":"2019","journal-title":"Biomolecules"},{"key":"B49","doi-asserted-by":"publisher","first-page":"108876","DOI":"10.1016\/j.intimp.2022.108876","article-title":"IL-38 in modulating hyperlipidemia and its related cardiovascular diseases","volume":"108","author":"Lai","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.cca.2022.09.017","article-title":"Interleukin-38 in atherosclerosis","volume":"536","author":"Zhang","year":"2022","journal-title":"Clin Chim Acta"},{"key":"B51","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/iid3.159","article-title":"The emerging role of interleukin-37 in cardiovascular diseases","volume":"5","author":"Zhuang","year":"2017","journal-title":"Immun Inflamm Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/B978-0-12-385961-7.00015-9","article-title":"Activin A in nonalcoholic fatty liver disease","volume":"85","author":"Yndestad","year":"2011","journal-title":"Vitam Horm"},{"key":"B53","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/biof.1723","article-title":"Novel roles of Tsukushi in signaling pathways and multiple disease processes","volume":"47","author":"Deng","year":"2021","journal-title":"Biofactors"},{"key":"B54","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/bs.apcsb.2017.01.002","article-title":"Cardiokines as modulators of stress-induced cardiac disorders","volume":"108","author":"Planavila","year":"2017","journal-title":"Adv Protein Chem Struct Biol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.molmed.2010.12.003","article-title":"The cardiokine story unfolds: ischemic stress-induced protein secretion in the heart","volume":"17","author":"Doroudgar","year":"2011","journal-title":"Trends Mol Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13578-023-01097-1","article-title":"Cardiac-to-adipose axis in metabolic homeostasis and diseases: special instructions from the heart","volume":"13","author":"Tang","year":"2023","journal-title":"Cell Biosci"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1220426","DOI":"10.3389\/fendo.2023.1220426","article-title":"Fibroblast growth factor 21 in metabolic syndrome","volume":"14","author":"Yang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1038\/ncomms3019","article-title":"Fibroblast growth factor 21 protects against cardiac hypertrophy in mice","volume":"4","author":"Planavila","year":"2013","journal-title":"Nat Commun"},{"key":"B59","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3389\/fendo.2015.00133","article-title":"FGF21 and cardiac physiopathology","volume":"6","author":"Planavila","year":"2015","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B60","doi-asserted-by":"publisher","first-page":"177356","DOI":"10.1016\/j.ejphar.2025.177356","article-title":"Hepatokines and their role in cardiohepatic interactions in heart failure","volume":"992","author":"Shouman","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.3390\/nu12061899","article-title":"The role of exercise in the interplay between myokines, hepatokines, osteokines, adipokines, and modulation of inflammation for energy substrate redistribution and fat mass loss: a review","volume":"12","author":"Gonzalez-Gil","year":"2020","journal-title":"Nutrients"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3390\/nu13041180","article-title":"Adiponectin: structure, physiological functions, role in diseases, and effects of nutrition","volume":"13","author":"Khoramipour","year":"2021","journal-title":"Nutrients"},{"key":"B64","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11154-021-09687-5","article-title":"Leptin as a key regulator of the adipose organ","volume":"23","author":"Pic\u00f3","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"B65","doi-asserted-by":"publisher","first-page":"578966","DOI":"10.3389\/fphys.2020.578966","article-title":"Adipokines: new potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases","volume":"11","author":"Recinella","year":"2020","journal-title":"Front Physiol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1139\/y2012-053","article-title":"Adipokines and the cardiovascular system: mechanisms mediating health and disease","volume":"90","author":"Northcott","year":"2012","journal-title":"Can J Physiol Pharmacol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"464","DOI":"10.6515\/ACS.202109_37(5).20210323B","article-title":"Visfatin as a promising marker of cardiometabolic risk","volume":"37","author":"Erten","year":"2021","journal-title":"Acta Cardiol Sin"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1126\/science.abn0910","article-title":"Liver-heart cross-talk mediated by coagulation factor XI protects against heart failure","volume":"377","author":"Cao","year":"2022","journal-title":"Science"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.cmet.2024.04.020","article-title":"Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periosti","volume":"36","author":"Xie","year":"2024","journal-title":"Cell Metab"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/ejhf.942","article-title":"Immune mechanisms in heart failure","volume":"19","author":"Zhang","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1161\/CIRCULATIONAHA.114.008788","article-title":"Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling","volume":"131","author":"Frieler","year":"2015","journal-title":"Circulation"},{"key":"B72","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/cvr\/cvw089","article-title":"Anti-platelet drugs attenuate the expansion of circulating CD14highCD16\u2009+\u2009monocytes under pro-inflammatory conditions","volume":"111","author":"Layne","year":"2016","journal-title":"Cardiovasc Res"},{"key":"B73","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1161\/CIRCRESAHA.109.199802","article-title":"Myeloid differentiation factor-88\/interleukin-1 signaling controls cardiac fibrosis and heart failure progression in inflammatory dilated cardiomyopathy","volume":"105","author":"Blyszczuk","year":"2009","journal-title":"Circ Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"237ra66","DOI":"10.1126\/scitranslmed.3008618","article-title":"The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota","volume":"6","author":"Balmer","year":"2014","journal-title":"Sci Transl Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.chom.2020.07.014","article-title":"Programing of an intravascular immune firewall by the gut microbiota protects against pathogen dissemination during infection","volume":"28","author":"McDonald","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1424308","DOI":"10.3389\/fimmu.2024.1424308","article-title":"Identification of common signature genes and pathways underlying the pathogenesis association between nonalcoholic fatty liver disease and heart failure","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12911-023-02342-w","article-title":"The consequences of data dispersion in genomics: a comparative analysis of data sources for precision medicine","volume":"23","author":"Costa","year":"2023","journal-title":"BMC Med Inform Decis Mak"},{"key":"B78","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/hmg\/ddab203","article-title":"False positive findings during genome-wide association studies with imputation: influence of allele frequency and imputation accuracy","volume":"31","author":"Zhang","year":"2021","journal-title":"Hum Mol Genet"},{"key":"B79","doi-asserted-by":"publisher","first-page":"hoae025","DOI":"10.1093\/hropen\/hoae025","article-title":"Inaccurate measures of outcomes in the two-sample Mendelian randomization of vitamin D with miscarriage","volume":"2024","author":"Yang","year":"2024","journal-title":"Hum Reprod Open"},{"key":"B80","doi-asserted-by":"publisher","first-page":"109431","DOI":"10.1016\/j.isci.2024.109431","article-title":"Shared genetic architecture and causal relationship between liver and heart disease","volume":"27","author":"Fang","year":"2024","journal-title":"iScience"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"key":"B82","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","article-title":"Non-invasive evaluation of liver fibrosis using transient elastography","volume":"48","author":"Castera","year":"2008","journal-title":"J Hepatol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3389\/fphar.2016.00159","article-title":"Non-invasive markers of liver fibrosis: adjuncts or alternatives to liver biopsy?","volume":"7","author":"Chin","year":"2016","journal-title":"Front Pharmacol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e3230","DOI":"10.1210\/clinem\/dgac292","article-title":"Serum thrombospondin-2 levels are closely associated with the severity of metabolic syndrome and metabolic associated fatty liver disease","volume":"107","author":"Wu","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B86","doi-asserted-by":"publisher","first-page":"101257","DOI":"10.1016\/j.xcrm.2023.101257","article-title":"Identification and multicentric validation of soluble CDCP1 as a robust serological biomarker for risk stratification of NASH in obese Chinese","volume":"4","author":"Jia","year":"2023","journal-title":"Cell Rep Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3748\/wjg.v19.i8.1158","article-title":"From fatty liver to fibrosis: a tale of \u201csecond hit\u201d","volume":"19","author":"Basaranoglu","year":"2013","journal-title":"World J Gastroenterol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metab Clin Exp"},{"key":"B89","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41392-022-01073-0","article-title":"Trends in insulin resistance: insights into mechanisms and therapeutic strategy","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduction Targeted Ther"},{"key":"B90","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.metabol.2014.04.003","article-title":"De novo lipogenesis in health and disease","volume":"63","author":"Ameer","year":"2014","journal-title":"Metab Clin Exp"},{"key":"B91","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41586-023-06497-4","article-title":"Identification of an alternative triglyceride biosynthesis pathway","volume":"621","author":"McLelland","year":"2023","journal-title":"Nature"},{"key":"B92","doi-asserted-by":"publisher","first-page":"zwae306","DOI":"10.1093\/eurjpc\/zwae306","article-title":"Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease: pathophysiology and diagnostic aspects","author":"M\u00f8ller","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s13577-024-01145-z","article-title":"Pathophysiology, molecular mechanisms, and genetics of atrial fibrillation","volume":"38","author":"Han","year":"2024","journal-title":"Hum Cell"},{"key":"B94","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/ejhf.1620","article-title":"Heart failure after treatment for breast cancer","volume":"22","author":"Boekel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1161\/CIRCULATIONAHA.106.632745","article-title":"Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction","volume":"114","author":"Borlaug","year":"2006","journal-title":"Circulation"},{"key":"B98","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jchf.2014.10.005","article-title":"Renin-angiotensin-aldosterone system activation during decongestion in acute heart failure: friend or foe?","volume":"3","author":"Verbrugge","year":"2015","journal-title":"JACC Heart Fail"},{"key":"B99","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.3949\/ccjm.73.Suppl_3.S19","article-title":"The role of vasopressin in congestive heart failure","volume":"73","author":"Goldsmith","year":"2006","journal-title":"Cleve Clin J Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","article-title":"Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease","volume":"15","author":"Anstee","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3349\/ymj.2020.61.10.860","article-title":"Association between atrial fibrillation and advanced liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"61","author":"Kang","year":"2020","journal-title":"Yonsei Med J"},{"key":"B102","doi-asserted-by":"publisher","first-page":"960259","DOI":"10.3389\/fcvm.2022.960259","article-title":"Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients","volume":"9","author":"Wang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B103","doi-asserted-by":"publisher","first-page":"e0142937","DOI":"10.1371\/journal.pone.0142937","article-title":"Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA study)","volume":"10","author":"K\u00e4r\u00e4j\u00e4m\u00e4ki","year":"2015","journal-title":"PLoS One"},{"key":"B104","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jhep.2022.05.030","article-title":"Liver stiffness not fatty liver disease is associated with atrial fibrillation: the Rotterdam study","volume":"77","author":"van Kleef","year":"2022","journal-title":"J Hepatol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"101171","DOI":"10.1016\/j.jhepr.2024.101171","article-title":"Inflammation in liver fibrosis and atrial fibrillation: a prospective population-based proteomic study","volume":"6","author":"Boeckmans","year":"2024","journal-title":"JHEP Rep"},{"key":"B106","doi-asserted-by":"publisher","first-page":"e005227","DOI":"10.1161\/JAHA.116.005227","article-title":"Relations of liver fat with prevalent and incident atrial fibrillation in the framingham heart study","volume":"6","author":"Long","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"B107","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1148\/radiol.2021204288","article-title":"Quantification of liver fat content with CT and MRI: state of the art","volume":"301","author":"Starekova","year":"2021","journal-title":"Radiology"},{"key":"B108","doi-asserted-by":"publisher","first-page":"e035371","DOI":"10.1161\/JAHA.123.035371","article-title":"Association between noninvasive liver fibrosis scores and heart failure in a general population","volume":"13","author":"Liu","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.cgh.2024.03.045","article-title":"Liver fibrosis assessed via noninvasive tests is associated with incident heart failure in a general population cohort","volume":"22","author":"Hydes","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1007\/s00392-023-02250-z","article-title":"Non-alcoholic fatty liver disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients","volume":"112","author":"Roderburg","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"e010841","DOI":"10.1161\/CIRCHEARTFAILURE.123.010841","article-title":"Sex and age differences in the association between metabolic dysfunction-associated fatty liver disease and heart failure: a prospective cohort study","volume":"17","author":"Wu","year":"2024","journal-title":"Circ Heart Fail"},{"key":"B112","doi-asserted-by":"publisher","first-page":"117269","DOI":"10.1016\/j.atherosclerosis.2023.117269","article-title":"Sex-specific differences in cardiovascular risk factors and implications for cardiovascular disease prevention in women","volume":"384","author":"Rajendran","year":"2023","journal-title":"Atherosclerosis"},{"key":"B113","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jacasi.2023.08.003","article-title":"Association of metabolic dysfunction-associated fatty liver disease with risk of HF and AF","volume":"3","author":"Ohno","year":"2023","journal-title":"JACC Asia"},{"key":"B114","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/apt.17747","article-title":"Editorial: resmetirom\u2014a promising treatment option for NASH and liver fibrosis","volume":"59","author":"Targher","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"B115","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/1472-6963-14-151","article-title":"Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings","volume":"14","author":"Niyomnaitham","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"B116","first-page":"e342","article-title":"Prescribing trend of pioglitazone after safety warning release in Korea","volume":"25","author":"Jeong","year":"2019","journal-title":"Am J Manag Care"},{"key":"B117","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"822","DOI":"10.7326\/M20-4648","article-title":"Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2020 updated U.S. department of veterans affairs and U.S. department of defense clinical practice guideline","volume":"173","author":"O'Malley","year":"2020","journal-title":"Ann Intern Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2024-001404","article-title":"Statin prescriptions and progression of advanced fibrosis risk in primary care patients with MASLD","volume":"11","author":"Schreiner","year":"2024","journal-title":"BMJ Open Gastroenterol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2147\/VHRM.S391808","article-title":"Repurposing metformin for the treatment of atrial fibrillation: current insights","volume":"20","author":"Sarkar","year":"2024","journal-title":"Vasc Health Risk Manag"},{"key":"B121","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1080\/00365520902845268","article-title":"Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial","volume":"44","author":"Haukeland","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1161\/CIRCULATIONAHA.118.034516","article-title":"Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke","volume":"138","author":"Verma","year":"2018","journal-title":"Circulation"},{"key":"B123","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"B124","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1097\/HEP.0000000000000855","article-title":"Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: a randomized, double-blind, placebo-controlled trial","volume":"80","author":"Cheung","year":"2024","journal-title":"Hepatology"},{"key":"B125","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.2147\/JIR.S506154","article-title":"Serum olink targeted proteomics identifies IL-17A as a prospective inflammatory marker for the prediction and diagnosis of kawasaki disease","volume":"18","author":"Tu","year":"2025","journal-title":"J Inflamm Res"},{"key":"B126","doi-asserted-by":"publisher","first-page":"100563","DOI":"10.1016\/j.jhepr.2022.100563","article-title":"A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis","volume":"5","author":"Harrison","year":"2023","journal-title":"JHEP Rep"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"key":"B128","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1573841\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T01:18:19Z","timestamp":1744075099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1573841\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":128,"alternative-id":["10.3389\/fcvm.2025.1573841"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1573841","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"article-number":"1573841"}}